Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2003
03/20/2003US20030054043 Thixotropic oil based vehicle for pharmaceutical compositions
03/20/2003US20030054038 Mixture of drug and enteric acid polymer; neutralization
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054036 Mixture of block polymer; solvent and drug
03/20/2003US20030054034 Water soluble film forming polymer and microbiocide oil
03/20/2003US20030054028 Sustained releasing drug in situ
03/20/2003US20030054017 Alcohol based topical anesthetic formulation and method
03/20/2003US20030054011 Anticancer agents
03/20/2003US20030054007 Intracellular protein delivery compositions and methods of use
03/20/2003US20030054005 Using monoclonal antibodies; polymerase chain reactions
03/20/2003US20030053986 Method of treating hepatitis C infection
03/20/2003US20030053983 Colloidal metal compositions and methods
03/20/2003US20030053982 Interferon attached to water soluble polyethylene glycol
03/20/2003US20030053981 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
03/20/2003US20030053978 Antitumor agents
03/20/2003US20030053973 Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
03/20/2003US20030053959 Breathing a dry powder; antidiabetic agent
03/20/2003US20030053957 Degradation-resistant glucocorticosteroid formulations
03/20/2003CA2460190A1 Transdermal administration of an enalapril ester
03/20/2003CA2459426A1 Human immunodeficiency virus envelope glycoprotein mutants and uses thereof
03/20/2003CA2459318A1 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
03/20/2003CA2459120A1 Human tissue urokinase type plasminogen activator formulation
03/20/2003CA2458547A1 Fluid-to-powder compositions
03/20/2003CA2458047A1 Compositions and methods of use of targeting peptides against placenta and adipose tissues
03/20/2003CA2457895A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
03/20/2003CA2457717A1 Use of compounds in a dry powder inhaler
03/20/2003CA2452194A1 Sustained release pharmaceutical compositions comprising a silicone support material
03/19/2003WO2002024001A2 Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use
03/19/2003EP1293209A1 Oral pharmaceutical dosage forms with reduced potential for drug abuse
03/19/2003EP1293206A1 Water-based liquid preparation
03/19/2003EP1293204A1 Urea-containing gel preparation
03/19/2003EP1293203A1 Alcohol based local anaesthetic formulation
03/19/2003EP1293195A1 Oral pharmaceutical dosage forms with reduced potential for drug abuse, comprising respiratory irritants or bitter substances
03/19/2003EP1293194A1 Physically stable sprayable gel composition
03/19/2003EP1293126A1 Ophthalmic solution and contact lens solution
03/19/2003EP1292709A1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
03/19/2003EP1292628A1 Process for the manufacture of hydrogel compositions and hydrogel compositions manufactured thereby
03/19/2003EP1292618A2 Vip-related peptides for the treatment of sexual disorders in women
03/19/2003EP1292612A2 Glycopeptide phosphonate derivatives
03/19/2003EP1292611A2 Glycopeptide carboxy-saccharide derivatives
03/19/2003EP1292609A2 Peptides, compositions and methods for the treatment of burkholderia cepacia
03/19/2003EP1292606A2 Positively-charged peptide nucleic acid analogs with improved properties
03/19/2003EP1292539A1 Micronised barium sulphate
03/19/2003EP1292381A1 Process and device for producing liquid dosage formulations
03/19/2003EP1292340A1 Transfection system
03/19/2003EP1292338A2 Stabiliser for radiopharmaceuticals
03/19/2003EP1292337A2 Multivalent platform molecules comprising high molecular weight polyethylene oxide
03/19/2003EP1292336A2 Conjugates of aminodrugs comprising an oxime bond
03/19/2003EP1292334A1 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
03/19/2003EP1292326A2 Recombinant human cln2 protein and methods of its production and use
03/19/2003EP1292325A1 Matrix protein compositions for dentin regeneration
03/19/2003EP1292316A1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
03/19/2003EP1292303A1 A stable pharmaceutical formulation comprising torsemide modification ii
03/19/2003EP1292298A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
03/19/2003EP1292293A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
03/19/2003EP1292286A1 Dry-powder pharmaceutical formulation for inhalation comprising alpha4-integrin antagonist
03/19/2003EP1292285A1 Delivery systems for bioactive agents
03/19/2003EP1292284A2 Encapsulation of polynucleotides and drugs into targeted liposomes
03/19/2003EP1292283A1 A medicinal aerosol formulation
03/19/2003EP1292282A2 Improved injectable dispersions of propofol
03/19/2003EP1292281A1 Novel tiotropium-containing inhalation powder
03/19/2003EP1292280A2 Multiple stimulus reversible hydrogels
03/19/2003EP1272531A4 Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
03/19/2003EP1151746B1 Microcapsules for sustained release of drugs
03/19/2003EP1137671B1 Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
03/19/2003EP1102579B1 Medicinal aerosol formulations
03/19/2003EP1049454B1 Cosmetic and dermatological preparations containing higher electrolyte concentrations
03/19/2003EP0980262B1 Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
03/19/2003EP0952853B1 Conjugate comprising an active agent, a polypeptide and a polyether
03/19/2003EP0949907B1 Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
03/19/2003EP0917472B1 Antiprotozoal composition
03/19/2003EP0871490B1 Branched hydrazone linkers
03/19/2003EP0833644B1 Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
03/19/2003EP0800364B1 Transdermal administration of apomorphine
03/19/2003EP0796106B1 Protracted glp-1 compositions
03/19/2003EP0774975B1 Use of starch for kinetic transdermal applications
03/19/2003CN1404486A Purified LH (Luteinizing hormone)
03/19/2003CN1404402A Radioactive therapeutic Liposomes
03/19/2003CN1404401A G-CSF conjugates
03/19/2003CN1404399A Novel non-antigenic mucosal adjuvant formulation for modulating the effects of substances, including vaccine antigens in contact with mucosal body surface
03/19/2003CN1404398A Improved DNA vaccines for production-type animals
03/19/2003CN1404397A Endoparasiticidal agent composition
03/19/2003CN1404389A Timed pulsatile drug delivery systems
03/19/2003CN1404364A Water containing soluble fiber
03/19/2003CN1403158A Eye drops containing chitosan derivative
03/19/2003CN1403093A Oral vanadium replenishing agent with bimetallic oxide as carrier and its prepn and usage
03/19/2003CN1403077A Slow-release preparation
03/19/2003CN1403076A Multi-particle improved release composition
03/19/2003CN1403075A Effervescent ointment for vagina and rectum administration and its prepn
03/19/2003CN1402974A Virus deactivating method with immobilized solvent or immobilized solvent-detergent
03/19/2003CN1103320C Releasing system for biological active reagent control releasing, medical product containing the same and its application
03/19/2003CN1103219C Formulations containing hyaluronic acid
03/19/2003CN1103217C Aqueous eye drops containing apafant as active ingredient
03/19/2003CN1103216C Pharmaceutical emulsions containing bioactive steroids
03/19/2003CA2422817A1 Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use
03/18/2003US6534663 Process for the preparation of materials with a high content of long chain polyunsaturated fatty acids
03/18/2003US6534591 First and second polymers containing nucleophilic groups and electrophylic groups capable of reacting to form covalent bonds between polymers, resulting in formation of three-dimensional matrix
03/18/2003US6534549 Mixture of water insoluble film-forming polymer and amylose; drug delivery to colon
03/18/2003US6534528 Treatment of a leg ulcer or a decubitus ulcer, wherein the ulcer is not infected, which comprises contacting the ulcer with a pharmaceutical which comprises a powder and at least one 1-hydroxy-2-pyridone
03/18/2003US6534505 Therapeutic polymorphs of a GABA-A alpha-5 inverse agonist and pamoate formulations of the same
1 ... 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 ... 1712